Certificate of Competence in Lymphoma (CCL)

Collaborating university: Ulm University

The Certificate of Competence in Lymphoma (CCL) was launched in 2013 and is the first competence programme to focus on the improvement of both the clinical and the scientific capability of oncologists, ensuring better-quality management of lymphoma patients.

This programme, which is offered on a part-time basis over 14 months, is divided into three attendance seminars and four online modules.

Upon successful completion of the programme, participants will obtain an academic certificate issued by the European School of Oncology and Ulm University assigning 14 European Credit Transfer and Accumulation System Points (ECTS), equalling a work load of 405 hours and a diploma supplement by Ulm University.

Download full CCL curriculum here

Eligibility

The programme is designed for oncologists and haematologists (medical oncology, haematology, internal medicine, radiation oncology, pathology), but it is equally accessible to graduates in natural sciences, who are engaged in the field of oncology, especially in the field of lymphoma.

1. Oncologists:
   1. Degree from a college or university¹ in a medical course of studies or an equivalent degree at the level of at least four years of studies (e.g. state examination in medicine) and
   2. At least two years of clinical experience in one of the following disciplines:
      • Medical Oncology
      • Haematology
      • Internal Medicine
      • Radiation Oncology
      • Pathology

2. Natural scientists:
   
   
   1. Degree from a college or university² in a course of studies in natural sciences or an equivalent degree at the level of at least three years of studies or in a course of studies with essentially the same contents³ at a college or university and
   2. At least two years of professional experience in oncology.
      
      
3. The following additional achievements will increase the assessment rate of the application:
   
   
   1. Further professional experience related to the course of studies
   2. Completion of an additional qualification in oncology (specialist training as a physician or international equivalent, e.g., board certified haematologist/oncologist)
   3. Publications, as evidenced by cumulative impact factors greater than 10
   4. At least one year of relevant oncological experience in a foreign country

It will not be possible to be enrolled in the programme if the applicant has lost the right to be examined at a German or foreign college or university in the master's course of studies in advanced oncology or other course of studies with essentially the same contents or is currently enrolled in an examination procedure in one of these courses of study.

(1) e.g. State examination in medicine
(2) At least a bachelor’s degree
(3) Examples of courses of study with essentially the same contents are biology, molecular medicine, biochemistry and pharmacology (state examination)

This programme takes place every two years and the 2021/2022 edition of this programme is already underway.

The next cohort will take place from 2023/2024, with applications opening in summer 2022.

The tuition fee is EUR 5,400. A discounted fee of EUR 3,000 is implemented and made available to participants from low, lower middle and upper middle-income economies as defined by The World Bank.

The tuition fee includes:

• Access to the modules via a dedicated online learning platform
• Access to seminars foreseen by the programme, including registration and accommodation
• Access to all exams required by the programme
• The administrative fee for the enrolment at Ulm University

Chairs

• James O. Armitage, University of Nebraska Medical Center, Omaha, US
• Manuela Hoechstetter, Schwabing Clinic, Munich, DE
• Franco Cavalli, European School of Oncology (ESO) and Oncology Institute of Southern Switzerland, Bellinzona, CH
• Stephan Stilgenbauer, Ulm University Hospital, DE

Scientific Directors

• Ranjana Advani, Stanford Cancer Institute, Stanford, US
• Elias Campo, University of Barcelona, Barcelona, ES
• Massimo Federico, University of Modena and Reggio Emilia, Modena, IT
• Gianluca Gaidano, Amedeo Avogadro University of Eastern Piedmont, Novara, IT
• Mary Gospodarowicz, Princess Margaret Hospital - University of Toronto, Toronto, CA
• Anton Hagenbeek, University of Amsterdam - Academic Medical Centre, Amsterdam, NL
• Andrew Lister, St. Bartholomew's Hospital, London, UK
• Julie M. Vose, University of Nebraska Medical Center, Omaha, US
• Emanuele Zucca, Oncology Institute of Southern Switzerland, Bellinzona, CH

Conceptual Development and Organisation

• Uta Schmidt-Strassburger, Ulm, DE
• Alexandra Zampetti, ESO, Bellinzona, CH